Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1999-01-29
2000-10-24
Fonda, Kathleen K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514317, 514331, 514547, A61K 31725
Patent
active
06136794&
ABSTRACT:
A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of a GPIIb/IIIa receptor antagonist or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin. A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of (2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]-propionic acid or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin.
REFERENCES:
patent: 4533549 (1985-08-01), Lasker
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 4678748 (1987-07-01), Sutka et al.
patent: 4739046 (1988-04-01), Di Luzio
patent: 4761402 (1988-08-01), Williams et al.
patent: 4877612 (1989-10-01), Berger et al.
patent: 4877777 (1989-10-01), DiLuzio
patent: 4971956 (1990-11-01), Suzuki et al.
patent: 4977165 (1990-12-01), Oinuma et al.
patent: 5057503 (1991-10-01), Czop et al.
patent: 5106616 (1992-04-01), McAnalley et al.
patent: 5106618 (1992-04-01), Beck et al.
patent: 5217898 (1993-06-01), Kaslow et al.
patent: 5288639 (1994-02-01), Burnie et al.
patent: 5374423 (1994-12-01), Klimpel et al.
patent: 5429818 (1995-07-01), Inzana
patent: 5470835 (1995-11-01), Kirkpatrick et al.
patent: 5531988 (1996-07-01), Paul
patent: 5538733 (1996-07-01), Emery et al.
patent: 5591434 (1997-01-01), Jenkins et al.
patent: 5763427 (1998-06-01), Weitz et al.
patent: 5858378 (1999-01-01), Bostwick
patent: 5880136 (1999-03-01), Duggan et al.
Cohen et al., "A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease", The New England Journal of Medicine, vol. 337, No. 7, pp. 447-452, (Aug. 14, 1997).
Clive Kearon, "Low-Molecular-Weight Heparin versus Unfractionated Heparin for Unstable Coronary Disease", The New England Journal of Medicine, vol. 338, No. 2, pp. 129-130 (Jan. 8, 1998).
Frederick et al., "The Protective Dose of the Potent GPIIb/IIIa Antagonist SC-54701A . . .", Circulation, vol. 93, No. 1, pp. 129-134 (Jan. 1, 1996).
Angus, K., "Cryptosporidiosis and AIDS", Bailliere's Clinical Gastroenterology, vol. 4, No. 2, pp 425-441 (Jun. 1990).
Ashman, R. et al., "Production and Function of Cytokines in Natural and Acquired Immunity to Candida albicans Infection", Microbiological Reviews, vol. 59. No. 4, pp. 646-672 (Dec. 1995).
Derwent Abstract for ZA9209143, Sep. 29, 1993, Acc. No. 93-386927/199348.
Barrios, C. et al., "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming", Eur. J. Immunol, vol. 22, pp. 1365-1372 (1992).
Carrow, E. et al., "Immunoregulation in Experimental Murine Candidiasis: Specific Suppression Induced by Candida albicans Cell Wall Glycoprotein", Infection and Immunity, vol. 49. No. 1, pp. 172-181 (Jul. 1985).
Cook J. et al., "Visceral Leishmaniasis in Mice: Protective Effect of Glucan", Journal of the Reticuloendothelial SocietyI, vol. 27, No. 6, pp. 567-573 (Jun. 1980).
Cook, J. et al., "Immunomodulation of Protozoan Diseases.sup.1,2 ", Surv. Immunol, Res. 2, pp. 243-245 (1983).
Crawford, F. et al., "Human Cryptosporidiosis", CRC Critical Reviews in Microbiology, vol. 16, Issue 2, pp. 113-159 (1988).
Cutler, J. et al., "Enhanced Antibody Responses Induced by Candida albicans in Mice", Infection and Immunity, vol. 38, No. 3, pp. 1102-1108 (Dec. 1982).
Harp, J. et al., "Protection of Calves with a Vaccine Against Cyrptosporidium Parvum", J. Parasitol., 81(1), pp. 54-57 (1995).
Holbrook, T. et al., "Glucan-Enhanced Immunogenicity of Killed Erythrocytic Stages of Plasmodium berghei", Infection and Immunity, vol. 32, No. 2, pp. 542-546 (May 1981).
Holbrook, T. et al., "Immunization of Mice Against Leishmania Donovani by Subcutaneous Injections of Dead Promastigotes", Am. J. Trop. Med. Hyg., vol. 32, No. 1, pp. 51-53 (1983).
Janoff, E. et al., "Cryptosporidium Species, a Protean Protozoan", Journal of Clinical Microbiology, vol. 25, No. 6, pp. 967-975 (Jun. 1987).
Jarecki-Black, J. et al., "Resistance Against Leismania donovani Induced with an Aluminum Hydroxide Vaccine", Annals of Clinical and Laboratory Science, vol. 18, No. 1, pp. 72-77 (Jan.-Feb.) 1988.
Laughon, B. et al., "Prevalence of Enteric Pathogens in Homosexual Men With and Without Acquired Immunodeficiency Syndrome", Gastroenterology, vol. 94, No. 4, pp. 984-993 (Apr. 1988).
Maheshwari, R. et al., "Immunoprotection by .crclbar.-1,3 glucan antigen combination in Plasmodium berghei infection in mice", Indian J. Med Res 89, pp. 396-403 (Nov. 1989).
Mencacci, A. et al., "A Mannoprotein Constituent of Candida albicans That Elicits Different Levels of Delayed-Type Hypersensitivity, Cytokine Production, and Anticandidal Protection in Mice", Infection and Immunity, vol. 62, No. 12, pp. 5353-5360 (Dec. 1994).
Nord, J. et al., "Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients", AIDS, vol. 4, No. 6, pp. 581-584 (1990).
Obaid, K. et al., Protective Effect of L. Donovani Antigens Using Glucan as an Adjuvant, Int. J. Immunopharmac, vol. 11, no. 3, pp. 229-235 (1989).
Oblack, D. et al., "Active Immunisation of Mice Against Muscle Damage Mediated by Candida Albicans", J. Med. Microbiol., vol. 12, pp. 503-505 (1979).
Peterson, C. et al., CA Abstract No. 120: 189727 WO9324649 A1 (Dec. 9, 1993).
Scaringi, L. et al., "Cell Wall Components of Candida albicans as Immunomodulators: Induction of Natural Killer and Macrophage-mediated Peritoneal Cell Cytotoxicity in Mice by Mannoprotein and Glucan Fractions", Journal of General Microbiology, vol. 134, pp. 1265-1274 (1988).
Segal, E., "Vaccines Against Fungal Infections", CRC Critical Reviews in Microbiology, vol. 14, Issue 3, pp. 229-271 (1987).
Tzipori, S. et al., "Chronic Cryptosporidial Diarrhoea and Hyperimmune Cow Colostrum", The Lancet, pp. 344-345 (Aug. 8, 1987).
Ungar, B., et al., "Cessation of Cryptosporidium-Associated Diarrhea in an Acquired Immunodeficiency Syndrome Patient After Treatment With Hyperimmune Bovine Colostrum", Gastroenterology, pp. 486-489 (Feb. 1990).
Vazquez, N. et al., "Activation of murine resident peritoneal macrophages by a cell wall extract of Candida albicans", Journal of Medical& Veterinary Mycology, vol. 33, pp. 385-393 (Jun. 1995).
Williams, D. et al., "Immunization Against Trypanosoma Cruzi: Adjuvant Effect of Glucan", Int. J. Immunopharmac, vol. 11, No. 4, pp. 403-410 (1989).
Yamaguchi, H. et al., "immunomodulating Activity of Antifungal Drugs", Annals of the New York Academy of Sciences, vol. 685, pp. 447-457 (1993).
Cook Jacquelynn J.
Gould Robert J.
Sax Frederic L.
Fonda Kathleen K.
Merck & Co. , Inc.
Parr Richard S.
Winokur Melvin
LandOfFree
Platelet aggregation inhibition using low molecular weight hepar does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Platelet aggregation inhibition using low molecular weight hepar, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Platelet aggregation inhibition using low molecular weight hepar will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1964164